CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 252 enrolled
Drug / intervention
Captopril +15 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00391846
NCT00391846Phase 4Completed

A Randomised, Single Blind, Multicentre, 9-month, Phase IV Study, Comparing Treatment Guided by Clinical Symptoms and Signs and NT-proBNP vs Treatment Guided by Clinical Symptoms and Signs Alone, in Patients With Heart Failure (HF) and Left Ventricular Systolic Dysfunction

AstraZeneca·interventional·Posted Oct 25, 2006·Updated Jun 25, 2012

In Brief

A Phase 4 clinical trial evaluating Captopril, Enalapril, and 14 other interventions for Heart Failure and Ventricular Dysfunction, Left. Completed, enrolled 252 participants across 39 sites.

Detailed Summary

The purpose is to study if HF treatment guided by NTproBNP in addition to clinical symptoms and signs is more effective than treatment guided by clinical symptoms and signs alone in patients with HF and left ventricular systolic dysfunction

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 25, 2006
Enrollment StartOct 1, 2006
Primary CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.7 years ago

Interventions

Captoprildrug

Enalaprildrug

Lisinoprildrug

Ramiprildrug

Trandolaprildrug

Bisoprololdrug

Carvediloldrug

Metoprolol succinatedrug

Candesartandrug

Valsartandrug

Eplerenonedrug

Spironolactonedrug

Diureticsdrug

HF treatment according to Swedish guidelinesdrug

Blood samplesprocedure

The Kansas City Cardiomyopathy Questionnaire (KCCQ)procedure